Skip to main content
. Author manuscript; available in PMC: 2019 Apr 1.
Published in final edited form as: Clin Exp Metastasis. 2018 Mar 13;35(4):247–254. doi: 10.1007/s10585-018-9877-y

Figure 4.

Figure 4

Systemic administration of PEG-GM-CSF does not increase recruitment of migrating tumor cells to tumors. (A) Blood half life of GM-CSF after a single intravenous injection of 0.05 mg/kg of PEG-GM-CSF. (B) Ex vivo bioluminescence measured in shGFP or shGM-CSF tumors in mice treated with daily injections of 20 pg PEG-GM-CSF. (C) Plasma levels of GM-CSF measured 3 and 10 days after the initiation of treatment. (D) Counts for blood cells before (Control) and at specified times following the initiation of PEG-GM-CSF treatment.